July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Stay up-to-date on the latest drugs in development.
Daily insulin dose linked to cancer risk in multivariable model, with increasing cancer incidence in low-, medium-, high-dose insulin groups
The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Limiting added sugar and refined grains helpful, but no added overall health benefit seen for cutting out legumes, fruits, and whole grains
As part of the state’s new budget, $50 million will go directly to the development of low-cost insulin products
Hemoglobin A1C may be lowered by interventions addressing food, education, housing
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn).
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.